Results 351 to 360 of about 213,598 (380)
Some of the next articles are maybe not open access.
International Journal of Immunopharmacology, 1994
T-cell adjuvancy involves the use of agents to stimulate preferentially delayed type hypersensitivity (DTH). Traditional adjuvants like Alum, Freunds, muramyl peptides, and endotoxins are not selective. Natural infection (e.g. vaccinia) may yield selective DTH. Low dose cyclophosphamide (CY) with mycobacteria was the first experimental T-cell adjuvant.
openaire +3 more sources
T-cell adjuvancy involves the use of agents to stimulate preferentially delayed type hypersensitivity (DTH). Traditional adjuvants like Alum, Freunds, muramyl peptides, and endotoxins are not selective. Natural infection (e.g. vaccinia) may yield selective DTH. Low dose cyclophosphamide (CY) with mycobacteria was the first experimental T-cell adjuvant.
openaire +3 more sources
Experientia, 1971
Wahrend sich bei Endotoxinen der Adjuvanseffekt proportional zur Antigenitat verhalt, ist diese Beziehung bei dem aus Tuberkelbazillen isolierten Wachs D nicht der Fall.
Tatsuro Ishibashi +3 more
openaire +3 more sources
Wahrend sich bei Endotoxinen der Adjuvanseffekt proportional zur Antigenitat verhalt, ist diese Beziehung bei dem aus Tuberkelbazillen isolierten Wachs D nicht der Fall.
Tatsuro Ishibashi +3 more
openaire +3 more sources
Adjuvant synergy: The effects of nasal coadministration of adjuvants
Immunology & Cell Biology, 2004Modern peptide and protein subunit vaccines suffer from poor immunogenicity and require the use of adjuvants. However, none of the currently licensed adjuvants can elicit cell‐mediated immunity or are suitable for mucosal immunization. In this study we explored the immunological effect of nasal co‐administration of adjuvants with distinct functions ...
Sterghios Moschos +3 more
openaire +3 more sources
Clinical Infectious Diseases, 1980
Nonreplicating, purified subunit or synthetic viral vaccines of the future are likely to be weak immunogens that will require immunopotentiation if they are to be effective. These marginal vaccines could be improved by combination with potent and safe immunologic adjuvants. The use of adjuvants should also reduce the amount of purified antigen required
openaire +2 more sources
Nonreplicating, purified subunit or synthetic viral vaccines of the future are likely to be weak immunogens that will require immunopotentiation if they are to be effective. These marginal vaccines could be improved by combination with potent and safe immunologic adjuvants. The use of adjuvants should also reduce the amount of purified antigen required
openaire +2 more sources
Emerging concepts in the science of vaccine adjuvants
Nature Reviews Drug Discovery, 2021Bali Pulendran, Prabhu S Arunachalam
exaly
An overview of cytokine used as adjuvants in fish: current state and future trends
Reviews in Aquaculture, 2021Chenghua Li
exaly
Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action
Nature Reviews Chemistry, 2021Carlo Pifferi +2 more
exaly
The Cellular Targets for the Action of Adjuvants: T-Adjuvants and B-Adjuvants
2008Jennifer M. Phillips, D. W. Dresser
openaire +2 more sources